InMed revises merger terms with Mentari, clarifying deal sequence and enabling additional pre-close financing

summarizeSummary

InMed Pharmaceuticals amended its merger agreement with Mentari Therapeutics, clarifying the deal sequencing and creating a pathway for Mentari to raise additional pre-closing financing that could impact the exchange ratio.

check_boxKey Events · M&A and Partnerships · INM

• Merger Agreement Amended

  On July 6, 2026, InMed, Mentari, and merger subs entered Amendment No. 1 to the May 19, 2026 merger agreement, introducing new terms.

• Sequencing Clarified

  InMed will change its name to Mentari Therapeutics, Inc. and redomesticate from British Columbia to Nevada before closing; any Nasdaq reverse split will occur prior to the First Effective Time.

• Additional Pre-Closing Financing Possible

  Amendment introduces a 'Company PIPE Amendment' mechanism allowing Mentari to raise additional private placement proceeds before closing, which would adjust the exchange ratio and could alter the ownership split.

• Tax Treatment Clarified

  The First and Second Mergers together are intended to qualify as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.

auto_awesomeAnalysis · INM · Life Sciences

The amendment to the all-stock reverse merger with Mentari Therapeutics introduces material new terms. It clarifies the transaction sequencing — InMed will change its name and redomesticate from British Columbia to Nevada before closing, and any Nasdaq reverse split will occur pre-merger. Critically, it creates a mechanism for Mentari to raise additional pre-closing private placement financing (a 'Company PIPE Amendment'), which would adjust the exchange ratio and could alter the ownership split. The tax treatment is also clarified as a tax-free reorganization. These changes refine the deal structure and introduce a new financing variable that could affect dilution for current InMed shareholders.